Methods and compositions for preventing and treating a disease related to glycan dysregulation
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.
1. A method of treating multiple sclerosis comprising:
administering to a subject having multiple sclerosis a therapeutically effective amount of a nutraceutical or pharmaceutical composition comprising a metabolite of a pathway for synthesis of a sugar donor for Mgat5 and a pharmaceutically acceptable or nutraceutically acceptable carrier,
wherein said metabolite is N-acetylglucosamine (GlcNAc) or N-acetylglucosamine-tetra-acetate; and
wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's multiple sclerosis.
2. The method of claim 1 , further comprising administering a therapeutically effective amount of a nutraceutical or pharmaceutical, composition comprising uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), uracil, or a nutraceutically acceptable derivative thereof, and a pharmaceutically acceptable or nutraceutically acceptable carrier.
3. The method of claim 2 , further comprising administering a therapeutically effective amount of a nutraceutical or pharmaceutical composition comprising Vitamin D3 and a pharmaceutically acceptable or nutraceutically acceptable carrier.
4. The method of claim 1 , further comprising administering a therapeutically effective amount of a nutraceutical or pharmaceutical composition comprising Vitamin D3 and a pharmaceutically acceptable or nutraceutically acceptable carrier.
5. The method of claim 1 , wherein the nutraceutical or pharmaceutical composition is administered orally.
6. A method for treatment of multiple sclerosis comprising:
administering to a subject having multiple sclerosis a nutraceutical or pharmaceutical composition comprising:
i. N-acetylglucosamine (GlcNAc) or N-acetylglucosamine-tetra-acetate;
ii. uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), uracil, or a nutraceutically acceptable derivative thereof;
iii. Vitamin D3; and
iv. a pharmaceutically acceptable or nutraceutically acceptable carrier;
wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's multiple sclerosis.
7. The method of claim 6 , wherein the nutraceutical or pharmaceutical composition is administered orally.
8. A method for treatment of multiple sclerosis comprising administering to a subject having multiple sclerosis a nutraceutical or pharmaceutical composition comprising therapeutically effective amounts of:
i. N-acetylglucosamine (GlcNAc) or N-acetylglucosamine-tetra-acetate; and
ii. uridine, uridine 5′ diphosphate (UDP), uridine 5′ monophosphate (UMP), uridine 5′ triphosphate (UTP), uracil, or a nutraceutically acceptable derivative thereof; and
iii. a pharmaceutically acceptable or nutraceutically acceptable carrier;
wherein the level of Mgat5 modified glycans is increased in the subject, thereby treating the subject's multiple sclerosis.
9. The method of claim 8 , wherein the nutraceutical or pharmaceutical composition is administered orally.
10. The method according to claim 2 , wherein said nutraceutically acceptable derivative is a salt, hydrate or ester.
11. The method according to claim 6 , wherein said nutraceutically acceptable derivative is a salt, hydrate or ester.
12. The method according to claim 8 , wherein said nutraceutically acceptable derivative is a salt, hydrate or ester.